Skip to main content

NeuBase Therapeutics, Inc.

NBSEDelisted May 16, 2024
Industry
Pharmaceutical Preparations
SEC CIK
0001173281

NeuBase Therapeutics, Inc. was delisted on May 16, 2024; its insiders filed their last Form 4 on Sep 18, 2023; 18 institutions reported holding it in 13F filings for Q1 2024, worth $177.1K in total; Greenlight Capital was the only superinvestor holding it.

Q2 2023 vs. Q1 2023

How the institutions holding NeuBase Therapeutics, Inc. changed between Q1 2023 and Q2 2023.

All holders in Q2 2023All holders in Q1 2023

13F holders of NBSE: Q1 2023 compared with Q2 2023
MeasureQ1 2023Q2 2023Change
Holders3626−10
SharesConverted for a 1-for-20 split463.8K578.9K+115.0K (+24.8%)
Value$1.72M$1.08M−$634.6K (−37.0%)

New holders (5)

Institutions that held NeuBase Therapeutics, Inc. at the end of Q2 2023 but not at the end of Q1 2023.

Institutions new to NBSE in Q2 2023
InstitutionSharesValue% of portfolio
Armistice Capital, LLC166,174$310.7K0.01%
Royal Bank of Canada283$1.00K0.00%
JPMorgan Chase & Co539$9970.00%
IFP Advisors, Inc105$4690.00%
Global Wealth Management Investment Advisory, Inc.12$220.00%

Sold out (15)

Institutions that held NeuBase Therapeutics, Inc. at the end of Q1 2023 and filed for Q2 2023 without it.